Abstract
Objectives Non-communicable diseases (NCDs) have recently been highlighted as important risk factors for COVID-19 fatality. We set out to investigate the association between NCDs and the risk of death from any infection in the pre-COVID-19 era.
Design Prospective population-based study
Setting UK Biobank
Participants 493,295 participants
Main outcome measures Infection death prior to December 31st 2019.
Results During 5,277,344 participant-years of follow-up, 1,385 infection deaths occurred, accounting for 5% of all deaths. Competing risks regression revealed that advancing age, male sex, smoking, socio-economic deprivation and all studied NCDs were independently associated with both the risk of infection death and non-infection death; ethnicity was associated with neither. Only smoking, socio-economic deprivation, hypertension, respiratory disease, chronic kidney disease, psychiatric disease and rheumatological disease were associated with greater hazard ratios for infection than non-infection death. Accrual of multimorbidity was also associated with a greater increases in the risk of infection death (HR 9.03 [95% confidence interval 6.61 to 12.34] for 5+ comorbidities versus none; p<0.001), than non-infection death (HR 5.68 [95% confidence interval 5.22 to 6.17] for 5+ comorbidities versus none; p<0.001).
Conclusions Diverse NCDs are associated with increased risk of infection death, suggesting that recently reported associations with COVID-19 death may be non-specific. Moreover, only a subset of NCDs, together with the accrual of multimorbidity, smoking and socio-economic deprivation, are associated with greater relative risks of infection death than other causes of death. Further research is needed to define why these risk factors are biased toward infection death so that more effective preventative strategies can be targeted to high-risk groups.
What is already known on this topic
Infection contributes to approximately one in five deaths globally and this often occurs in people with non-communicable diseases (NCDs).
Many NCDs have recently been highlighted as risk factors for fatal COVID-19 infection.
What this study adds
Whilst diverse NCDs are associated with greater risk of infection death, only some pose greater hazards of infection than non-infection death.
The association of many NCDs with fatal COVID-19 infection is unlikely to be specific to this pathogen.
Competing Interest Statement
AM has undertaken consultancy work in relation to giant cell arteritis for Roche, Chugai, GlaxoSmithKline, Sanofi and Regeneron Pharmaceuticals, with all funding paid directly into a research account. MTK has received speaker fees from Merck, Novo Nordisk and unrestricted research awards from Medtronic. All other authors have no disclosures. KKW has received speaker fees from Medtronic, Livanova, St. Jude Medical, Pfizer, Bayer and BMS.
Funding Statement
No specific funding was required for this research, but some authors are or were paid by the British Heart Foundation. At no time did any authors, nor their institutions, receive other payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank received ethical approval from the NHS Research Ethics Service (11/NW/0382); we conducted this analysis under application number 59585.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The UK Biobank dataset is available to all bona fide researchers for all types of health-related research which is in the public interest.
